Ponezumab

A4DAB210 | Phase-II

Target APP

Isotype / Subclass G2 / None

Company

Rinat Neuroscience Pfizer

Clinical Status Phase-II

Format Whole mAb

Synonyms

PF-04360365 PF04360365 PF-4360365 PF4360365 RN 1219 RN-1219 RN1219

pH Formulation —

IMGT PubChem (135354668) PubChem (160687959) PubChem (404772575) PubChem (472422736) PubChem (472435539) PubChem (472440379) PubChem (481155528) PubChem (505863164) Thera-SAbDab YAbS

Avg A4D Score

-0.6488

Score Range

-0.66 to -0.64

Structures

2

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB210_3u0t_D_C	3u0t	100%	-0.6417	7.0	4.0	-0.075	-0.7137
A4DAB210_3u0t_B_A	3u0t	100%	-0.6559	7.0	4.0	0.0094	-0.7401

Ponezumab

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2